To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
Age and Gender: Patients aged 18 to 80 years (inclusive of boundary values), regardless of gender.
Diagnosis and Treatment: Patients with head and neck cancer (including nasopharyngeal carcinoma) who have been confirmed by histopathology and require radical radiotherapy or postoperative adjuvant radiotherapy.
Performance Status: Patients with an ECOG Performance Status score of 0 to 2.
Consent: Patients who voluntarily agree to participate in this study and sign the informed consent form.
Prior Radiotherapy: Patients with a history of prior radiotherapy to the target area.
Baseline Skin Condition: Baseline skin condition in the treatment area that may interfere with efficacy assessment (e.g., presence of open wounds, infection, rash, psoriasis, etc.).
Systemic Diseases: Presence of connective tissue diseases or other systemic dermatoses.
Known Allergies: Known allergy to any component of the investigational product (Meilian Fuxin Solution).